Long-term effect of xamoterol in patients with dilated cardiomyopathy.

概要

論文の詳細を見る
Xamoterol (100 mg bd), a β1-partial agonist, was given to 13 patients with dilated cardiomyopathy for 12 months. The long-term effects after 3 and 12 months of treat ment with xamoterol were assessed. Xamoterol reduced cardiothoracic ratio from 57 ± 8 at baseline to 54±7 after 3 months and 54± 7% after 12 months of treatment (both P <0.05), and increased exercise tolerance from 4.8± 2.3 at baseline to 6.8± 2.4 and 6.5±2.3min, respectively (both P<0.01). Echocardiographic fractional shortening increased from 13±6 to 21±9 (P<0.01) and 19±11% (P<0.05). Pulmonary wedge pressure (PAW) during exercise at the same work load decreased from 40±12 to 25± 9 mmHg (P<0.01) at 3 months and 32±16 mmHg (NS) at 12 months. Resting PAW at 3 months decreased and was unchanged at 12 months. Exercise heart rate decreased from 118±9 to 106±6 beats/min at 3 months (P<0.01) and was unchanged at 12 months. The density of the β-receptors in lymphocytes increased from 1, 024±413 at baseline to 1, 976±497 (P<0.01) at 3 months and 1, 584±650 sites/cell (NS) at 12 months while the respective values for the affinity of theβ-receptors were 0 .67±0.27, 1.60±0.42 (P<0.01) and 1.21±0.54 nM (P<0.05).<BR>It may be concluded that xamoterol improves exercise tolerance, haemodynamics, and subjective symptoms by its partial agonist action during long-term treatment.
一般社団法人日本臨床薬理学会の論文